DEMYELINATING DISEASES: Edited by Hans-Peter Hartung
Cree, Bruce A.C.a; Mares, Janb; Hartung, Hans-Peterc
aDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA
bDepartment of Neurology, University Hospital and Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
cDepartment of Neurology, Medical Faculty and Center for Neurology and Neuropsychiatry, LVR Klinikum, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
Correspondence to Bruce A.C. Cree, MD, PhD, MAS, Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA 94158, USA. Tel: +1 415 353 2069; fax: +1 415 353 2633; e-mail: [email protected]
doi: 10.1097/WCO.0000000000000700
Erratum
Figure 7 in the article, ‘Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm’ which published in the June 2019 issue of Current Opinion in Neurology, included an error .
Authors confirmed Ozanimod had no impact on EDSS in either SUNBEAM or RADIANCE. The correct text from the figure should read: “A significant reduction in risk of 3m-CDP vs. IFN β-1a was not reached in the pooled analysis of SUNBEAM and RADIANCE studies.”
Current Opinion in Neurology.
32(5):782,
October 2019.
